New study tracks gene mutations in breast cancer patients on alpelisib
NCT ID NCT05022342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed observational study in India enrolled 595 people with HR-positive, HER2-negative advanced or metastatic breast cancer who were already taking alpelisib plus fulvestrant. Researchers looked for PIK3CA gene mutations in tumors and tracked how well the cancer responded to treatment. The goal was to better understand the link between these mutations and patient outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alpelisib plus fulvestrant
- What this could lead to
- If successful, this could help doctors understand which patients with advanced breast cancer might benefit most from alpelisib treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Hyderabad, Andhra Pradesh, 500034, India
-
Novartis Investigative Site
Guwahati, Assam, 781023, India
-
Novartis Investigative Site
Kochi, Kerala, 682041, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400071, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 440001, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 441108, India
-
Novartis Investigative Site
Pune, Maharashtra, 411004, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110060, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110092, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751003, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751007, India
-
Novartis Investigative Site
Chandigarh, Punjab, 160055, India
-
Novartis Investigative Site
Ludhiana, Punjab, 141008, India
-
Novartis Investigative Site
Jaipur, Rajasthan, 302017, India
-
Novartis Investigative Site
Sherilingampally, Telangana, 500019, India
-
Novartis Investigative Site
Howrah, West Bengal, 711103, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700029, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700054, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700063, India
-
Novartis Investigative Site
Ahmedabad, 380054, India
-
Novartis Investigative Site
Kanpur, 208002, India
-
Novartis Investigative Site
Kolkata, 700016, India
-
Novartis Investigative Site
Kolkata, 700026, India
-
Novartis Investigative Site
Kolkata, 700107, India
-
Novartis Investigative Site
Puducherry, 605006, India
-
Novartis Investigative Site
Udaipur, 313011, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?